论文部分内容阅读
目的探讨血小板a-颗粒膜糖蛋白(CD62p)、溶酶体颗粒膜糖蛋白(CD63)与高血压分期、危险度分层的关系。方法应用流式细胞术测定85例高血压患者及29例正常对照者的血小板CD62p、CD63含量,同时用放免法检测血浆内皮素。结果高血压病组血小板CD62p、CD63阳性的百分率[(7·64±4·9)%,(9·43±3·77)%]显著高于正常对照组[(0·54±0·34)%,(2·84±1·12)%](P<0·05~<0·001),且随着高血压患者血压分期水平及危险度分层递增而增加,差异显著(P<0·05~<0·001)。血小板CD62p、CD63与血浆内皮素呈显著正相关(r分别为0·41,0·40,P均<0·05)。结论活化血小板测定对于高血压病分期、危险度分层具有显著的相关性,对于高血压恶化的早期诊断和治疗具有重要的临床应用价值。
Objective To investigate the relationship between platelet a-granulocyte glycoprotein (CD62p), lysosomal granule membrane glycoprotein (CD63) and hypertension stage and risk stratification. Methods Flow cytometry was used to determine the platelet CD62p and CD63 levels in 85 hypertensive patients and 29 normal controls. Plasma endothelin was also detected by radioimmunoassay. Results The percentages of positive CD62p and CD63 in the hypertensive group were significantly higher than those in the control group [(7.44 ± 4.94)%, (9.43 ± 3.77)%] [(0.54 ± 0.34 ), (2.84 ± 1.12)%] (P <0.05-0.001), and with the increase of blood pressure staging and risk stratification in hypertension patients, the difference was significant (P < 0 · 05 ~ <0 · 001). Platelet CD62p, CD63 and plasma endothelin showed a significant positive correlation (r = 0.41, 0.40, P <0.05). Conclusion Activated platelet assay has a significant correlation with staging and risk stratification of hypertension, and has important clinical value for the early diagnosis and treatment of the worsening of hypertension.